FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2055430811> ?p ?o ?g. }

• W2055430811 endingPage "158" @default.
• W2055430811 startingPage "153" @default.
• W2055430811 abstract "It is certainly acknowledged, albeit rather recently, that adequate control of hyperglycemia in type II diabetic patients is generally poor at best. A heightened realization of this fact and hopes that control of hyperglycemia may prevent complications or limit their severity have spawned newer approaches toward achieving improved glycemic control through changes in standard programmatic care with diet, exercise, oral agents or insulin therapy, and management of hypertension and obesity. Insulin taken at bedtime to control noctural hepatic glucose output, multiple doses of regular insulin coupled with frequent blood sugar measurements, and combined insulin and oral agents are approaches currently under trial in several centers. Interest in combination therapy stems in part from residual concern that hyperinsulinemia may contribute to the development of atherosclerosis, and to evidence that the sulfonylureas, especially the second-generation drugs, improve sensitivity to the glycolytic effects of insulin, thereby reducing insulin resistance. More than a dozen serious studies of combined therapy have been reported since the early 1980s. This study is unique, however, in several respects since non-obese, type II, insulin-requiring diabetic persons were chosen for study and were hospitalized prior to initiating the actual investigation in order to secure optimal diabetic control and thereby ensure greater sensitivity of the beta cell. Twenty type II diabetic patients were studied in a double-blinded, placebo-controlled trial with insulin and glyburide. All were treated with intermediate-acting insulin and adjustments were made as necessary to achieve optimal control, after which the patients were randomly assigned to either an insulin-and-glyburide program or to insulin-plus-placebo treatment. Thereafter, patients were followed in an outpatient setting for four months, after which time they were rehospitalized for final assessment. Standard chemistries, urinary glucose, glycosylated hemoglobins, and urinary C-peptide levels were measured. The fasting serum glucose level remained normal in the glyburide/insulin-treated group, whereas these were significantly higher in the placebo-plus-insulin group at four and at eight weeks. Glycosylated hemoglobin levels rose progressively in the placebo- and insulin-treated group and by 16 weeks were significantly higher than measurements from the insulin- and glyburide-treated group of patients (p < 0.05). Although one- and two-hour postprandial serum glucose levels were unacceptably high in both groups, these values did not worsen in the insulin-plus-glyburide-treated patients, whereas the levels were significantly higher in the placebo-treated subjects. It is believed that the results of this carefully controlled, prospective study are sufficiently noteworthy to warrant a larger multicenter trial of combined therapy in order to gain additional data for statistical analysis. This is needed if an answer to the question, “Does combined insulin and oral agent therapy in type II diabetics really work?” and if so, “For whom?”" @default.
• W2055430811 created "2016-06-24" @default.
• W2055430811 creator A5085999084 @default.
• W2055430811 creator A5090322534 @default.
• W2055430811 date "1988-11-01" @default.
• W2055430811 modified "2023-10-17" @default.
• W2055430811 title "New modalities in diabetes treatment" @default.
• W2055430811 cites W171367838 @default.
• W2055430811 cites W1971735908 @default.
• W2055430811 cites W1983010315 @default.
• W2055430811 cites W1995713402 @default.
• W2055430811 cites W2001497361 @default.
• W2055430811 cites W2006071812 @default.
• W2055430811 cites W2008264538 @default.
• W2055430811 cites W2009996271 @default.
• W2055430811 cites W2033974890 @default.
• W2055430811 cites W2040536132 @default.
• W2055430811 cites W2043205397 @default.
• W2055430811 cites W2055905772 @default.
• W2055430811 cites W2057847857 @default.
• W2055430811 cites W2059404137 @default.
• W2055430811 cites W2073141187 @default.
• W2055430811 cites W2075350527 @default.
• W2055430811 cites W2085756765 @default.
• W2055430811 cites W2089615575 @default.
• W2055430811 cites W2093244675 @default.
• W2055430811 cites W2112969133 @default.
• W2055430811 cites W2132665064 @default.
• W2055430811 cites W2146540689 @default.
• W2055430811 cites W2152677046 @default.
• W2055430811 cites W2161986582 @default.
• W2055430811 cites W2292274763 @default.
• W2055430811 cites W2335159383 @default.
• W2055430811 cites W2339785199 @default.
• W2055430811 cites W2917185555 @default.
• W2055430811 cites W4298285293 @default.
• W2055430811 cites W1975369901 @default.
• W2055430811 doi "https://doi.org/10.1016/0002-9343(88)90409-3" @default.
• W2055430811 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3143264" @default.
• W2055430811 hasPublicationYear "1988" @default.
• W2055430811 type Work @default.
• W2055430811 sameAs 2055430811 @default.
• W2055430811 citedByCount "8" @default.
• W2055430811 countsByYear W20554308112021 @default.
• W2055430811 crossrefType "journal-article" @default.
• W2055430811 hasAuthorship W2055430811A5085999084 @default.
• W2055430811 hasAuthorship W2055430811A5090322534 @default.
• W2055430811 hasConcept C126322002 @default.
• W2055430811 hasConcept C134018914 @default.
• W2055430811 hasConcept C177713679 @default.
• W2055430811 hasConcept C2777180221 @default.
• W2055430811 hasConcept C2777391703 @default.
• W2055430811 hasConcept C2778537899 @default.
• W2055430811 hasConcept C2779306644 @default.
• W2055430811 hasConcept C2780473172 @default.
• W2055430811 hasConcept C2780668416 @default.
• W2055430811 hasConcept C2780988686 @default.
• W2055430811 hasConcept C555293320 @default.
• W2055430811 hasConcept C71924100 @default.
• W2055430811 hasConceptScore W2055430811C126322002 @default.
• W2055430811 hasConceptScore W2055430811C134018914 @default.
• W2055430811 hasConceptScore W2055430811C177713679 @default.
• W2055430811 hasConceptScore W2055430811C2777180221 @default.
• W2055430811 hasConceptScore W2055430811C2777391703 @default.
• W2055430811 hasConceptScore W2055430811C2778537899 @default.
• W2055430811 hasConceptScore W2055430811C2779306644 @default.
• W2055430811 hasConceptScore W2055430811C2780473172 @default.
• W2055430811 hasConceptScore W2055430811C2780668416 @default.
• W2055430811 hasConceptScore W2055430811C2780988686 @default.
• W2055430811 hasConceptScore W2055430811C555293320 @default.
• W2055430811 hasConceptScore W2055430811C71924100 @default.
• W2055430811 hasIssue "5" @default.
• W2055430811 hasLocation W20554308111 @default.
• W2055430811 hasLocation W20554308112 @default.
• W2055430811 hasOpenAccess W2055430811 @default.
• W2055430811 hasPrimaryLocation W20554308111 @default.
• W2055430811 hasRelatedWork W2014369012 @default.
• W2055430811 hasRelatedWork W2032225465 @default.
• W2055430811 hasRelatedWork W2056849036 @default.
• W2055430811 hasRelatedWork W2057434408 @default.
• W2055430811 hasRelatedWork W2083753940 @default.
• W2055430811 hasRelatedWork W2094672900 @default.
• W2055430811 hasRelatedWork W2097857221 @default.
• W2055430811 hasRelatedWork W2151350502 @default.
• W2055430811 hasRelatedWork W2410789767 @default.
• W2055430811 hasRelatedWork W2418646588 @default.
• W2055430811 hasVolume "85" @default.
• W2055430811 isParatext "false" @default.
• W2055430811 isRetracted "false" @default.
• W2055430811 magId "2055430811" @default.
• W2055430811 workType "article" @default.